Salubris Biotherapeutics has received EMA approval to start a Phase 1 clinical trial of JK06 for treating solid tumors that express the 5T4 protein

JK06 is a first-in-class quadrivalent, biparatopic antibody drug conjugate (ADC) that selectively targets 5T4 with an MMAE payload

The drug has shown promising results including high affinity for 5T4, rapid internalization, and a favorable safety profile

The Phase 1 trial will be an open-label, dose-escalation study to evaluate JK06’s safety, pharmacokinetics, and preliminary efficacy, with recruitment expected to begin in Q3 2024

5T4 is associated with cancer aggressiveness and poor treatment outcomes, and JK06 aims to deliver cytotoxic agents more effectively to tumors expressing this protein